





OUR MISSION:
TO TRANSFORM PIONEERING
SCIENCE INTO THERAPIES
BY CATALYSING PARTNERSHIPS
BETWEEN ACADEMIA
AND INDUSTRY

This year marked a step change with the opening of our own research capabilities within the new **Milner Therapeutics Institute** on the biomedical campus (p5). This research institute — made possible through the support of Dr Jonathan Milner and the University of Cambridge — provides a physical hub for collaboration, where academics, start-ups and industry scientists are working side by side at the bench. This has allowed us to build our own in-house research programme for target discovery, using artificial intelligence and genetic analysis within the **Centre for Pathway Analysis** (p6–8), and support entrepreneurs through the **Start Codon accelerator** (p12). New cross-sector partnerships with a target discovery focus such as the **AstraZeneca–Cancer Research UK Functional Genomics Centre** are also based in the institute (p14). Together these teams are creating exciting opportunities to engage with the research, clinical and biotech community in Cambridge to make a tangible difference to therapies.

In addition to our new research capabilities, the new institute will become the headquarters of the **Milner Therapeutics Consortium** (consisting of the University of Cambridge, Wellcome Sanger Institute, Babraham Institute and 8 pharma companies (p17–19)). This Consortium remains central to our vision to enable collaborations across academia and industry with the entire Cambridge community. It has resulted in 22 collaborative projects within 11 University Departments in the areas of oncology, infectious disease, CNS and chemistry. A key goal is also to drive pre-competitive projects in which several pharmaceutical companies work together with an academic, sharing resource and expertise. We are delighted that our first such project is up and running (p19) and more are now being planned.



*Dr Kathryn Chapman
Deputy Director*



*Professor Tony Kouzarides
Director*

**ACADEMICS
IN
RESIDENCE**

**CENTRE FOR
PATHWAY ANALYSIS**
COMPUTATIONAL
BIOLOGY GROUP
FUNCTIONAL
GENOMICS GROUP

**MILNER
INSTITUTE**

**CAMBRIDGE
CENTRE FOR
PROTEOMICS**

**CRUK
ASTRAZENECA
FUNCTIONAL
GENOMICS
CENTRE**



**DRIVE
COLLABORATIVE
PROJECTS**

**WHAT
WE DO**



**ACCELERATE
THERAPEUTIC
COMPANIES**

START CODON

INVESTMENT, MENTORSHIP
AND SPACE FOR INNOVATIVE START-UPS


A GLOBAL THERAPEUTIC ALLIANCE

NETWORKING EVENTS WITH:

- 54 AFFILIATED COMPANIES
- 14 AFFILIATED INSTITUTIONS ACROSS FOUR CONTINENTS
- 8 PHARMA COMPANIES
- 3 ACADEMIC INSTITUTES
- 2 VENTURE PARTNERS

CONNECT
ACADEMIA
+ INDUSTRY

ENABLE
RESEARCH IN
CAMBRIDGE



10 INNOVATION REPS
17 SCIENTIFIC ADVISORS

ACADEMIC-PHARMA CONSORTIUM

- 3 CAMBRIDGE ACADEMIC INSTITUTIONS
- 8 PHARMA COMPANIES
- 22 PROJECTS IN 11 DEPARTMENTS
- £3.8 MILLION INVESTMENT IN CAMBRIDGE RESEARCH



Jeffrey Cheah
Biomedical Centre



MILNER THERAPEUTICS INSTITUTE

The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration.

RESEARCH INSTITUTE

The research institute opened last summer in the new **Jeffrey Cheah Biomedical Centre** on the Cambridge Biomedical Campus, providing a physical hub for collaboration between industry and academia. Scientists from academia, pharma and biotech are working together in this common space, creating a unique research environment that breaks down barriers between these sectors.

The institute houses four research units:

- Centre for Pathway Analysis (p6–8)
- Start Codon accelerator programme (p12)
- Cambridge Centre for Proteomics (p13)
- AstraZeneca–Cancer Research UK Functional Genomics Centre (p14)

GLOBAL OUTREACH PROGRAMME

The Milner Therapeutics Institute has built a global research community of 81 organisations working together across academia and industry, with Cambridge providing a hub of expertise. The outreach programme is delivered through our:

- Milner Therapeutics Consortium (p17–19)
- Global Therapeutic Alliance (p16)
- Onco-innovation programme at the Cancer Research UK Cambridge Centre (p10–11)

Our neighbours in the building include the Wellcome–MRC Cambridge Stem Cell Institute (led by Professor Tony Green) and the new Cambridge Institute of Therapeutic Immunology and Infectious Disease (led by Professor Ken Smith), which is enabling new collaborations in areas of therapeutic priority.

CENTRE FOR PATHWAY ANALYSIS

The Centre for Pathway Analysis provides a unique interactive and multifaceted environment for therapeutic innovation where academics, pharma and biotech work side-by-side. In the Centre, we are developing our own research programme and target discovery pipeline (p7–8). The methods and approaches we are developing are disease-agnostic but we are currently focused on applying these in oncology and CNS diseases.



Dr Rebecca Harris
Drug Discovery Programme Manager

DISEASE SIGNATURE INTERROGATION


Led by Dr Rebecca Harris, a target discovery and functional validation programme will be initiated in the coming year. To date, we have worked with external researchers who have performed experimental validation and functional interrogation of the disease signatures identified through computational biology in their own labs. The opening of the Institute and our purpose built space now provides the opportunity to establish our own in house experimental capabilities. In collaboration with Cambridge researchers who have expertise with complex cellular or organoid disease models, our strategy is to develop robust assays for medium-throughput genetic and chemical screening for target identification and functional validation. These specialist facilities, set up and managed by our facilities manager Gian-marco Melfi, will also provide new opportunities for more pre-competitive collaborative projects between Cambridge academics and our Consortium partners (p17–19).



Clockwise:
Gian-marco Melfi
Scientific Facilities Coordinator
Chloe Caley
Finance, HR & Administration Coordinator
Ben Pearson
Research Laboratory Technician

DISEASE SIGNATURE IDENTIFICATION THROUGH AI



The aim of our computational biology team, led by Dr Namshik Han, is to create an atlas of disease mechanisms through the integration and interrogation of large multi-omic datasets. The team are using bespoke machine learning methods to identify new signatures of disease and therapeutic targets (see *figure, page 8*), as well as network analysis to gain a deep understanding of the underlying causes of disease. Working closely in collaboration with the medical research charity LifeArc and also with Storm Therapeutics, the team has been able to develop and validate methodology with clear applications in drug discovery. This unit is also working with researchers and clinicians throughout Cambridge who have unique patient datasets and disease models, and it is this sharing of expertise that ensures results are biologically interpretable and can inform go/no go decision making in drug discovery. Our approaches have been applied to target identification and repositioning and are applicable across many areas of healthcare including early detection and personalised medicine.



Dr Namshik Han
Computational Biology Programme Lead



Left to right
Georgia Tsagkogeorga
Méabh MacMahon
Woochang Hwang
Soorin Yim
Sofia Ramani






Figure: A Circos plot showing clear target-disease association for a target gene (T) that can influence almost the whole disease-specific network (TCGA) through direct interactions (PPI) and well-known genes in a given disease area (MASTER).

COMPANIES AND ACADEMICS IN RESIDENCE

Selected start-up companies, and junior academic research groups whose research interests are aligned with ours, are housed in the Centre for Pathway Analysis. Our Milner Therapeutics Consortium pharma partners also have a physical presence, through scientists working on collaborative projects with Cambridge researchers and through hot-desking. Rockend Ltd, a start-up company working on the application of stem cell technology towards new therapies, is currently based at the Milner Therapeutics Institute and current academics in residence are:

KOSTAS TZELEPIS

The *Tzelepis group* (Milner Therapeutics Institute and Wellcome Sanger Institute) is uncovering epigenetic mechanisms that are implicated in devastating malignancies including acute myeloid leukaemia (AML). His work previously identified several novel RNA-binding/modifying proteins that are essential for AML cell survival, including the RNA methyltransferase METTL3 and the splicing kinase SRPK1. Now, the group is investigating the role of RNA modifications and splicing in cancer initiation and maintenance. As part of the Centre for Pathway Analysis, Kostas will bring vital know-how in both the design of CRISPR screening for improved disease understanding, and also the development of sophisticated *in vivo* and *in vitro* assays for genetic and pharmacological validation of promising targets.



MANAV PATHANIA

The *Pathania group* (Milner Therapeutics Institute, Dept Oncology and CRUK Cambridge Centre) have a central focus on developing new mouse models for children's brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic and epigenetic weaknesses in these tumour models, they hope in the longer term to pave the way to more targeted, precise treatments that can be tailored to each patient. A key area of interest includes how dynamic chromatin remodelling is regulated in neural stem cells and how it becomes co-opted in brain cancer, including paediatric high-grade glioma.



ONCO-INNOVATION AT THE CANCER RESEARCH UK CAMBRIDGE CENTRE

The Cancer Research UK Cambridge Centre (CRUK CC) unites more than 700 researchers and healthcare professionals across the academic and industrial sectors within the Cambridge area. The Centre's common mission is to end death and disease caused by cancer, through research, treatment and education. Through the

*Dr Rebecca Harris
Programme Manager*



integration and development of scientific expertise and innovative technologies, the Centre is adopting a proactive and personalised approach to detect cancer earlier and treat it more precisely. The Centre is organised into 12 programmes, covering different cancer disease areas and cross-cutting themes.

The Onco-Innovation programme, administered and delivered by the Milner Therapeutics Institute, sits at the interface between academia and industry, focusing on the application of multidisciplinary science to better understand disease mechanisms and thereby inform cancer detection and patient treatment. One key function of the Onco-Innovation programme is to catalyse and enable




*Professor Tony Kouzarides
Programme Lead*



*Dr Susan Galbraith
Programme Lead*

exchange of expertise and resources between industry, clinicians and academia to deliver maximum benefit to patients. We deliver this by establishing academic/industry collaborative projects, either within a researcher's own labs or within the Institute's Centre for Pathway Analysis. So far 10 projects across 6 CRUK CC programmes have been established (see page 18), resulting in investment of >£1.5million in CRUK CC laboratories. With members from across multiple academic disciplines including biology, maths, chemistry, physics, engineering and computing, Onco-Innovation is well placed to promote innovation and development of new technologies. We work closely with Start Codon (p12) to provide entrepreneurship opportunities to the cancer research community.




We welcome applications for membership to the Onco-Innovation programme. To find out more please do get in touch: oncoinnovation@crukcambridgecentre.org.uk

START CODON

The life science and healthcare business accelerator Start Codon, (the vision of which was conceived and created together with the Milner Therapeutics Institute), has officially moved into the Milner Therapeutics Institute. Start Codon, represented by Dr Jason Mellad (CEO), Daniel Rooke (Head of Operations and Legal), Sakura Holloway (Head of Diligence), Michael Salako (Senior Investment Associate) and Silvia Baudone (Programme and Partnerships Manager), is the first accelerator in Cambridge to provide start-up companies with a combination of seed funding, facilities, mentoring and access to a dedicated team and network of industry leading contacts. Welcomed alongside them are also the first four cohort companies to join the accelerator. Each company will be based at the Milner Therapeutics Institute for 6 months, before moving on to the next stage of their development.

In conjunction with the accelerator programme, Start Codon have joined Cancer Research UK's Entrepreneurial Programmes Initiative, which aims to promote the development of new business ventures within academia and encourage entrepreneurship. Start Codon's role focuses on the Cambridge cluster, to educate a multi-disciplinary oncology research community about entrepreneurship, company formation, operations and fundraising, with the goal of supporting the development of viable start-up businesses that will address unmet medical needs. Start Codon is now accepting applications for its second cohort of companies, commencing August 2020. Early stage start-up companies in the life sciences and healthcare space are invited to apply via the website.



CAMBRIDGE CENTRE FOR PROTEOMICS

The Cambridge Centre for Proteomics (CCP) is an internationally renowned proteomics facility which strives for the development and application of robust proteomics technology. It is comprised of a core facility that can be accessed through collaboration or fee-for-service managed by Dr Mike Deery, and a research group directed by Professor Kathryn Lilley. CCP is a member of the Department of Biochemistry and located within the Milner Therapeutics Institute.

CCP houses state-of-the-art mass spectrometers and the core facility provides services ranging from sample preparation to quantitative proteomics workflows and data analysis.

CCP's research centres around themes which couple genomics and proteomics approaches with data analysis using machine learning approaches. Its research aims to understand how localised translation, differential post transcriptional and translational processing, interacting partners and protein structure affect the subcellular location of proteins and their ability to carry out multiple functions.



*Professor Kathryn Lilley
Director*

To enable us to reach these aims, we have developed a set of technologies and workflows, both experimental and computational. These technologies include: LOPIT (the location of organelle proteomics using isotope tagging), which allows the simultaneous mapping of proteins to their subcellular location on a cell-wide scale; and OOPS (orthogonal organic phase extraction), which efficiently samples the RNA binding proteome.

CCP research is funded by the BBSRC and the Wellcome Trust and has multiple collaborations with industrial partners. It is also part of EPIC-XS, a recently funded European Proteomics Infrastructure Consortium including top proteomics laboratories in Europe.



JOINT ASTRAZENECA-CANCER RESEARCH UK FUNCTIONAL GENOMICS CENTRE

The Joint AstraZeneca-Cancer Research UK (CRUK) Functional Genomics Centre is delivering state-of-the-art functional genetic screens, cancer modelling and big data processing – all aimed at accelerating the discovery of new cancer medicines.

Based at the Milner Therapeutics Institute, the Functional Genomics Centre is developing novel CRISPR technologies to better understand the biology of cancer, creating biological models that may be more reflective of human disease and advancing computational approaches to better analyse big datasets. A goal of the new centre is the identification of novel drug targets to better treat cancer patients and overcome drug resistance. AstraZeneca and CRUK have independent use of the Centre's facilities but are jointly developing state-of-the-art functional genomic technologies. CRUK and AstraZeneca scientists are working alongside each other to facilitate collaboration, technical innovation and scientific progress. The Milner Therapeutics Institute provides a unique collaborative space and environment on the Cambridge Biomedical Campus (CBC) which is convenient for both AstraZeneca and CRUK, with the dedicated space the Functional Genomics Centre needs.





GLOBAL THERAPEUTIC ALLIANCE

The Global Therapeutic Alliance, led by Dr Alison Schuldt, aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The **Milner Therapeutics Consortium** is central to this aim (p17–19), and the Alliance has been expanded with the Affiliated Company and Affiliated Institutions scheme to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge.



Dr Alison Schuldt
Global Alliance Manager

The **Milner annual symposium** is a key event for bringing our network together and building new collaborations. With more than 400 attendees from both academia and industry, this forum is rapidly growing — highlighting the excellent progress being made at this cross-sector interface and the strong appetite from the community to work together towards the common goal of transforming pioneering science into therapies. The symposium is complemented by the monthly **Milner seminar series**, smaller workshops and partnering events on industry prioritised research topics. These have led to new collaborative projects, successful academic–industry funding applications for shared equipment and investment of industry into biotech.

81 ORGANIZATIONS ACROSS FOUR CONTINENTS



Top: Nikki Mann
Communications & Events Coordinator
Katie Hiscock, Events Coordinator

MILNER THERAPEUTICS CONSORTIUM

The Consortium has been active since June 2015 and is based on a research agreement signed by three academic centres in Cambridge and eight pharmaceutical companies: the University of Cambridge, the Wellcome Sanger Institute and the Babraham Institute; and Astex, AstraZeneca, GlaxoSmithKline, Shionogi, Pfizer, Janssen R&D, Ferring and Eisai. The agreement is designed to facilitate the speedy exchange of reagents and information for research collaboration with academics across Cambridge. Each industry partner within the Milner Therapeutics Consortium has set aside funds for collaborative projects, which are open to any therapeutic area and are expected to lead to joint publications.

The Innovation Board brings together the industrial and academic partners of the Consortium to determine the overarching challenges facing the pharmaceutical industry and predict future needs. It enables companies to collaborate on common research projects related to targets, technologies and therapeutic areas.



There have been **22 Consortium projects** across eleven Departments and Institutes of the University and the Babraham to date; these include a focus on oncology, infectious diseases, CNS and chemistry (an investment of **£3.8 million** by our industry partners) (p18). The projects are broad in remit and can include access to compounds, datasets, equipment or know-how in a particular technique. In some cases, an industry scientist has come to work in the academic's lab, and in others an academic post has been funded specifically for the project. The emphasis in all our collaborations is on mutual sharing of expertise. In 2019, we initiated our first pre-competitive project with multiple pharmaceutical companies collaborating with one academic researcher (see p19). The project is being carried out in the Centre for Pathway Analysis which provides an unparalleled environment for cross-sector research.

CONSORTIUM PROJECTS

Lucy Colwell (Dept Chemistry)

The use of artificial intelligence technologies in fragment-based drug discovery (Astex)

Martin Welch (Dept Biochemistry)

Advancing disease understanding and drug discovery in infectious diseases* (Shionogi)

Anthony Davenport (Dept Medicine)

A drug re-purposing strategy for treatment of angina* (AstraZeneca)

Trevor Robbins (Dept Psychology)

Rodent models for remediating attention, working memory and impulsivity (Shionogi)

Angela Roberts (Dept PDN)

Understanding mechanisms of anhedonia and its treatment

Gillian Griffiths (Cambridge Institute for Medical Research)

Strategies to influence T-cell mediated tumour killing* (AstraZeneca)

Emma Rawlins & Joo Hyeon Lee

(Wellcome CRUK Gurdon Institute &

Wellcome MRC Cambridge Stem Cell Institute)

Elucidating signalling pathways that drive lung development in improved organoid models* (AstraZeneca)

Ludovic Vallier (Wellcome MRC Cambridge Stem Cell Institute)

Novel therapeutics for liver disease (Ferring & GlaxoSmithKline)

David Belin (Dept Psychology)

Towards the identification of novel biobehavioural markers related to addiction (Shionogi)

Projects with Cancer Research UK Cambridge Centre

Gerard Evan (Dept Biochemistry)

Uncovering how Myc-mediated gene expression supports the tumour environment* (AstraZeneca)

Frank McCaughan (Depts Biochemistry & Medicine)

Identifying potential therapies for early squamous lung cancer (Janssen R&D)

Gerard Evan & Cathy Wilson (Dept Biochemistry)

Strategies to prevent the progression to pancreatic adenocarcinoma* (AstraZeneca)

Carlos Caldas (CRUK Cambridge Institute)

Investigating how different sub-types of breast cancer respond to different treatments* (AstraZeneca)

Simon Cook (Babraham Institute)

Investigating modulators of the ERK/MAPK pathway* (Astex)

Tony Kouzarides (Wellcome CRUK Gurdon & Milner Institutes)

Insights into the use of PROTAC molecules as a therapeutic strategy (GlaxoSmithKline)

Frank McCaughan (Depts Biochemistry & Medicine)

Identifying targets to prevent squamous carcinogenesis progression* (AstraZeneca)

Suzanne Turner (Dept Pathology)

Mechanisms of resistance to ALK inhibition in neuroblastoma* (AstraZeneca)

Bertie Göttgens (Wellcome MRC Cambridge Stem Cell Institute)

Capturing the early stages of acute myeloid leukaemia to evaluate new therapeutics* (AstraZeneca)

Charlie Massie, Simon Pacey & Vincent

Gnanapragasam (Early Detection Programme, CRUK Cambridge Centre, Dept Oncology; Depts Oncology and Surgery)

Developing a pathway for precision medicine in early stage prostate cancer; to reduce radical treatment in active surveillance populations and improve outcomes for patients with aggressive disease (AstraZeneca)

*completed projects



SIMON COOK

ONCOLOGY: Investigating mechanisms of ERK1/2 inhibition

Simon Cook (Babraham Institute) has collaborated with Astex to investigate

the significance of different modes of ERK1/2 inhibition in cell lines and the consequences for cancer cell growth inhibition and adaptive resistance. Targeting the ERK1/2 pathway with BRAF or MEK inhibitors in melanoma has been very successful but many cancers do not respond or adapt to current BRAF or MEK inhibitors by reinstating ERK1/2 signalling. This project involved a detailed study of how different ERK inhibitors alter downstream pathway signalling, and revealed that a dual-mechanism inhibitor may provide more prolonged pathway inhibition, with potential implications for ongoing inhibitor development in the clinic.

PUBLICATIONS

- Sipthorp J et al. *Bioconjugate Chem.* (2017).
- Kidger A et al. *Pharmacol Ther.* (2018) (Review).
- Kidger et al. *Mol. Cancer Therapy* (2019).

“ This consortium provides a unique opportunity to combine our expertise on disease modelling with the therapeutic knowledge from the pharmaceutical industry. This combination will allow the identification of new target genes for drug development against a major unmet clinical need ”

Ludovic Vallier



LUDOVIC VALLIER

DISEASE MODELS: Novel therapeutics for liver disease

Non-alcohol fatty liver disease/non-alcoholic steatohepatitis (NAFLD/

NASH) are becoming a leading cause of liver disease in developed countries and, in many cases, organ transplantation is the only available treatment. Development of new therapies is currently impaired by the absence of physiologically relevant disease models. To address this limitation, Ludovic Vallier (Wellcome MRC Cambridge Stem Cell Institute) is working with GlaxoSmithKline and Ferring Pharmaceuticals to identify and validate new therapeutic targets in liver disease through CRISPR/Cas9-based genetic screens. Of particular interest, this consortium aims to identify new genes protecting liver cells against toxicity induced by fatty acids. This project will bring together a novel *in vitro* human model for NAFLD/ NASH established in the Vallier group and NASH/ NAFLD expertise from the two companies.

PUBLICATIONS

- Hannan NR, Segeritz CP, Touboul T & Vallier L. *Nature Protoc.* 8, 430-437, doi:nprot.2012.153 [pii]10.1038/nprot.2012.153 (2013).
- Rashid ST et al. *J. Clin. Invest.* 120, 3127-3136 (2010).
- Segeritz CP et al. *J. Hepatol* pii: S0168-8278(18)32113-5. doi: 10.1016/j.jhep.2018.05.028. (2018).

AFFILIATED COMPANIES

The Affiliated Company scheme, established in October 2016, now includes 54 organizations which bring diverse expertise and resource to the Milner network.

The institute promotes interactions between affiliated companies and academic, pharmaceutical or biotechnology partners, with the aim of building a cohesive community with an aligned vision. Our annual symposium is a key event — supported by the affiliated companies — for catalysing new opportunities for collaboration.

The affiliated companies include global pharma and biotech companies as well as a significant number of start-ups and SMEs with their own drug pipeline, many of which have arisen from research in Cambridge. Our activities are supported by a broad range of life science companies providing essential drug discovery expertise. The affiliate companies span disease areas from cancer and neurodegeneration to rare disease and there is a strong cohort of companies focusing on AI and data science, emphasizing the rapidly increasing application of this technology in biomedical research.

PHARMA & BIOTECH

PHARMA & BIOTECH



START-UPS & SMEs*



* Small and medium-sized enterprises

LIFE SCIENCE TOOLS & SERVICES

AI & DATA SCIENCE



LIFE SCIENCES



DIAGNOSTICS



AFFILIATED INSTITUTIONS

The Affiliated Institutions programme, established in October 2017, now includes 14 academic institutions across four continents. These partners share our vision of developing new models for research collaboration across industry and academia to transform pioneering science into therapies. They have free access to our annual symposium and themed events; we also provide them with contacts throughout the Global Therapeutic Alliance, fostering research opportunities and supporting engagement with industry in their own institutions.



VENTURE PARTNERS

The Affiliated Venture Partners programme, operational since October 2017, provides mentoring and potential funding opportunities for the Milner Therapeutics Institute and its Global Therapeutic Alliance, and especially for our in-house company accelerator Start Codon.

OUR ORGANIZATIONAL STRUCTURE

INNOVATION BOARD

- Dr Susan Galbraith, *AstraZeneca*
- Dr David Andrews, *AstraZeneca*
- Dr John Lyons, *Astex*
- Dr Rab Prinjha, *GlaxoSmithKline*
- Victoria Higgins, *GlaxoSmithKline*
- Dr David Shields, *Pfizer*
- Dr Ryuichi Kiyama, *Shionogi*
- Dr Yoshiro Shiba, *Shionogi*
- Dr Morten Persson, *Ferring*
- Dr Declan Jones, *Ferring*
- Professor Ludovic Vallier, *University of Cambridge*
- Dr Mathew Garnett, *Wellcome Sanger Institute*
- Professor Michael Wakelam, *Babraham Institute (until March 2020)*
- Dr Simon Cook, *Babraham Institute*
- Dr Lilian Alcaraz, *Janssen R&D*
- Dr Ann Connolly, *Janssen R&D*
- Dr Peter Atkinson, *Eisai*
- Dr Andy Takle, *Eisai*
- Professor Greg Hannon, *CRUK Cambridge Institute*
- Dr Kathryn Chapman, *Milner Therapeutics Institute*
- Professor Tony Kouzarides, *Milner Therapeutics Institute*

GOVERNANCE BOARD: UNIVERSITY OF CAMBRIDGE

- Professor Chris Abell
- Professor Anna Philpott
- Professor Richard Gilbertson
- Professor Patrick Maxwell
- Professor Andy Neely
- Professor Julie Ahringer
- Dr Isabelle de Wouters
- Dr Michael Godfrey
- Dr Katherine Wallington
- Professor Tony Kouzarides
- Dr Kathryn Chapman

MANAGEMENT BOARD

- Professor Tony Kouzarides
- Dr Kathryn Chapman
- Professor Greg Hannon
- Professor Ludovic Vallier
- Dr Mathew Garnett

SCIENTIFIC ADVISORS AT UNIVERSITY OF CAMBRIDGE

- Dr Sarah Bohndiek
- Professor Roger Barker
- Professor Carlos Caldas
- Professor John Danesh
- Professor Gordon Dougan
- Professor Rebecca Fitzgerald
- Professor Andres Floto
- Professor Tony Green
- Professor Brian Huntley
- Professor Arthur Kaser
- Professor Nick Morell
- Professor Willem Ouwehand
- Professor Stephen O’Rahilly
- Dr Emma Rawlins
- Professor David Rubinsztein
- Professor Ken Smith

UNIVERSITY INNOVATION REPRESENTATIVES (CURRENT)

- Dr Stephen Smith
- Dr James Richards
- Dr Hiran Prag
- Dr Kirsty Hooper
- Dr Qianxin Wu
- Dr Eugene Park
- Dr Chun Gong
- Dr Jenny Hirst
- Dr Paulo Rodrigues
- Dr Chiara Guiliano

HOW TO ENGAGE WITH US

Please write to us (contact@milner.cam.ac.uk) if you would like to engage with the Institute for a new partnership, research project, Consortium or Affiliated membership. We can provide for:

ACADEMICS

- Opportunities to partner with industry for early stage research collaborations
- Pre-agreed T&Cs to accelerate contracts
- Access for selected projects to advanced platforms in Centre for Pathway Analysis
- Links to AZ/CRUK Functional Genomics Centre

INDUSTRY

Consortium membership

- A gateway to academics and other industry members for research collaboration
- Pre-agreed T&Cs to accelerate contracts
- Board seat for strategic input into drug discovery pipeline and first sight of projects
- Priority access to Centre for Pathway Analysis
- Dedicated company profile at annual symposium and throughout Cambridge

ENTREPRENEURS

- Opportunities for significant investment, research space and mentorship through Start Codon accelerator



Affiliated partnership

- Opportunities to partner with academics and pharma companies
- Visible profile as Alliance partners and as sponsors of annual symposium
- Access to and presentation opportunities at biotech-focused events (e.g. bespoke workshops and Milner seminar series)

INVESTORS

- First sight of start-ups
- Access to research community, companies and start-ups at annual symposium, seminars and workshops

OUR FUNDERS



LifeArc



ACADEMIA

*Transforming pioneering
science into therapies*

INDUSTRY



**UNIVERSITY OF
CAMBRIDGE**

contact@milner.cam.ac.uk | www.milner.cam.ac.uk